Home › Funds › a16z Capital Management, L.L.C. › AKTS
a16z Capital Management, L.L.C. position in AKTS
AKTIS ONCOLOGY INC · Health Care
a16z Capital Management, L.L.C. reported holding 415,000 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$13.4M, representing 0.09% of its reported portfolio and ranking #14 among its reported holdings. a16z Capital Management, L.L.C. has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How a16z Capital Management, L.L.C.'s AKTS position evolved
a16z Capital Management, L.L.C. first disclosed a stake in AKTS in Q1 2026 at 415,000 shares (US$7.4M). The position peaked in Q2 2026 at 415,000 shares, worth US$13.4M. Across 2 filings, a16z Capital Management, L.L.C. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 415,000 shares valued at US$13.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 415.00K | $7.42M | New |
| Q2 2026 | 415.00K | $13.38M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AKTS and 13F data
AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AKTS
- MPM BioImpact LLC 4.84M sh · $155.86M · Q2 2026
- EcoR1 Capital, LLC 4.82M sh · $155.49M · Q2 2026
- Blue Owl Capital Holdings LP 3.07M sh · $98.95M · Q2 2026
- RTW INVESTMENTS, LP 1.59M sh · $51.31M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.31M sh · $42.36M · Q2 2026
- BAKER BROS. ADVISORS LP 996.35K sh · $32.11M · Q2 2026
- Octagon Capital Advisors LP 960.85K sh · $30.97M · Q2 2026
- Merck & Co., Inc. 952.84K sh · $30.71M · Q2 2026
- TCG Crossover Management, LLC 696.56K sh · $22.45M · Q2 2026
- Avidity Partners Management LP 484.20K sh · $15.61M · Q2 2026
More on a16z Capital Management, L.L.C.
FAQ
How long has a16z Capital Management, L.L.C. held AKTS?
a16z Capital Management, L.L.C. has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is a16z Capital Management, L.L.C.'s current position in AKTS?
As of Q2 2026, a16z Capital Management, L.L.C. holds 415.00K shares of AKTS (AKTIS ONCOLOGY INC), valued at $13.38M, representing 0.09% of its reported portfolio and ranking #14.
Has a16z Capital Management, L.L.C. been buying or selling AKTS?
In the latest 13F filing (Q2 2026), a16z Capital Management, L.L.C. held unchanged its position in AKTS. The position peaked in Q2 2026 at 415.00K shares.
Which other funds hold AKTS?
Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 121 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.